168 related articles for article (PubMed ID: 28145497)
1. Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid.
Li X; Sun W; Li J; Wang M; Zhang H; Pei L; Boyce BF; Wang Z; Xing L
Sci Rep; 2017 Feb; 7():41358. PubMed ID: 28145497
[TBL] [Abstract][Full Text] [Related]
2. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin E3 ligase Wwp1 negatively regulates osteoblast function by inhibiting osteoblast differentiation and migration.
Shu L; Zhang H; Boyce BF; Xing L
J Bone Miner Res; 2013 Sep; 28(9):1925-35. PubMed ID: 23553732
[TBL] [Abstract][Full Text] [Related]
4. Tea polysaccharide inhibits RANKL-induced osteoclastogenesis in RAW264.7 cells and ameliorates ovariectomy-induced osteoporosis in rats.
Xu H; Yin D; Liu T; Chen F; Chen Y; Wang X; Sheng J
Biomed Pharmacother; 2018 Jun; 102():539-548. PubMed ID: 29587240
[TBL] [Abstract][Full Text] [Related]
5. Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
Dela Cruz A; Grynpas MD; Mitchell J
Am J Physiol Endocrinol Metab; 2016 May; 310(10):E811-20. PubMed ID: 27006198
[TBL] [Abstract][Full Text] [Related]
6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
7. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
Herrak P; Görtz B; Hayer S; Redlich K; Reiter E; Gasser J; Bergmeister H; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2004 Jul; 50(7):2327-37. PubMed ID: 15248234
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis.
Sudhoff H; Jung JY; Ebmeyer J; Faddis BT; Hildmann H; Chole RA
Ann Otol Rhinol Laryngol; 2003 Sep; 112(9 Pt 1):780-6. PubMed ID: 14535562
[TBL] [Abstract][Full Text] [Related]
10. The skeletal impact of the chemotherapeutic agent etoposide.
Koh AJ; Sinder BP; Entezami P; Nilsson L; McCauley LK
Osteoporos Int; 2017 Aug; 28(8):2321-2333. PubMed ID: 28429052
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
[TBL] [Abstract][Full Text] [Related]
12. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
13. Clinically Relevant Concentrations of Ketamine Inhibit Osteoclast Formation In Vitro in Mouse Bone Marrow Cultures.
Du E; McAllister P; Venna VR; Xiao L
J Cell Biochem; 2017 Apr; 118(4):914-923. PubMed ID: 27775174
[TBL] [Abstract][Full Text] [Related]
14. Effects of two novel bisphosphonates on bone cells in vitro.
Evans CE; Braidman IP
Bone Miner; 1994 Aug; 26(2):95-107. PubMed ID: 7994190
[TBL] [Abstract][Full Text] [Related]
15. Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption.
Sasaki T
Microsc Res Tech; 2003 Aug; 61(6):483-95. PubMed ID: 12879416
[TBL] [Abstract][Full Text] [Related]
16. A novel anti-osteoporotic agent that protects against postmenopausal bone loss by regulating bone formation and bone resorption.
Yang YT; Meng JH; Hu B; Ma CY; Zhao CC; Teng WS; Hong JQ; Li SH; Jiang GY; Wang C; Zhou CH; Yan SG
Life Sci; 2018 Sep; 209():409-419. PubMed ID: 30096387
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
18. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
19. Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion.
Chen F; Dai Z; Kang Y; Lv G; Keller ET; Jiang Y
Osteoporos Int; 2016 Apr; 27(4):1469-1476. PubMed ID: 26556733
[TBL] [Abstract][Full Text] [Related]
20. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.
Hirbe AC; Rubin J; Uluçkan O; Morgan EA; Eagleton MC; Prior JL; Piwnica-Worms D; Weilbaecher KN
Proc Natl Acad Sci U S A; 2007 Aug; 104(35):14062-7. PubMed ID: 17715292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
